AnodyneWiki

Zolpidem

Zolpidem
Zolpidem
Salts
[]
Zolpidem hydrobromide
Zolpidem hydrobromide
Zolpidem hydrochloride
Zolpidem hydrochloride
Zolpidem hemitartrate
Zolpidem hemitartrate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass307.40 g/mol [1]
Melting point193-197 [1]
Solubility23 mg/mL at 20 C [1]
Predicted LogP2.5 [1]
Structural Identifiers
[]
Molecular formulaC19H21N3O
IUPAC nameN,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide
SMILESCC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C
InChIInChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
InChIKeyZAFYATHCZYHLPB-UHFFFAOYSA-N
CAS number82626-48-0
UNII7K383OQI23
PubChem CID5732
Pharmacokinetics[]
Onset15 minutes (oral spray), 30 minutes (oral tablets)[3]
Elimination half-life2–3 hours[4]
Duration of action3–6 hours (extended release) (duration & elimination varies by gender & age)[5][6][7]
MetabolismLiver through CYP3A4 (~60%), CYP2C9 (~20%), and CYP1A2 (~14%)[8]
ExcretionKidney (56%), fecal (34%)[9]
Routes of administrationBy mouth, sublingual, oromucosal (spray), rectal
Dependence liabilityPhysical: High Psychological: Moderate[10]
Addiction liabilityHigh
Toxicity
[]
Rat:
- Oral: 695 mg/kg
 [1]

Zolpidem (also known as Zolpidemum, Sanval, Zolpidem civ, Edlular, Zolpi Lich, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide, Sl 800750 23 n or Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-) is a depressant substance of the imidazopyridine class.

Chemistry

Salts []

Zolpidem is typically found in the form of its hydrobromide, hydrochloride and hemitartrate salts.

 []

Zolpidem is achiral.

Zolpidem matches Lipinski's rule of five.

There are currently 3 reagent-interactions on

ReagentColor changeDescription
Marquisno color change
Meckeno color change
Mandelinno color change

Pharmacology

Mechanism of action []

Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic substance with a chemical structure that is not related to the structure benzodiazepines, barbiturates, pyrrolopyrazines, pyrazolopyrimidines or other drugs exerting hypnotic effects. It interacts with a _GABA-BZ_ receptor complex and shares various pharmacological properties with the _benzodiazepine_ class of drugs. Subunit binding of the _GABAA_ receptor chloride channel macromolecular complex is thought to lead to the sedative, anticonvulsant, anxiolytic, and myorelaxant drug effects of zolpidem. The main regulatory site of the GABAA receptor complex can be found on its _alpha (α) subunit_ and is called the _benzodiazepine_ (BZ) or _omega (ω)_ receptor. At least three different subtypes of the (ω) receptor have been identified to this date. In contrast to benzodiazepine drugs, which are found to modulate all benzodiazepine receptor subtypes in a non-selective fashion, zolpidem binds the (BZ1) receptor specifically with a potent affinity for the alpha 1/alpha 5 subunits (in vitro). More recent studies suggest that zolpidem binds primarily to the alpha 1, 2, and 3 subunits of the GABA receptor,,, and not the alpha 5 subunit. The (_BZ1_) receptor is found primarily on the Lamina IV of the brain sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. Specific and selective binding of zolpidem on the (BZ1) receptor is not considered absolute, however, this binding could potentially explain the relative lack of myorelaxant and anticonvulsant activity in animal studies in addition to the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

induction / metabolism / inhibition140
shared target38
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
shared target35
metabolism / inhibition17

Medical side effects []

302 side effects listed on drug labels in (zolpidem).

  • Nasopharyngitis
  • Somnolence
  • Drowsiness
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Asthenia
  • Fatigue
  • Ataxia
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Feeling strange
  • Diplopia
  • Dyspepsia
  • Headache
  • Hiccups
  • Nervous system disorder
  • Upper respiratory tract infection
  • Urinary tract infection
  • Euphoric mood
  • Insomnia
  • Insomnia exacerbated
  • Chronic insomnia
  • Visual impairment
  • Visual disturbance
  • Sinusitis
  • Vertigo
  • Back pain
  • Influenza
  • Lethargy
  • Pharyngitis
  • Dry mouth
  • Disorientation
  • Nightmare
  • Anterograde amnesia
  • Abdominal pain
  • Gastrointestinal pain
  • Depression
  • Depression aggravated
  • Dermatitis
  • Rash
  • Muscle spasms
  • Cramps of lower extremities
  • Palpitations
  • Dizziness
  • Syncope
  • Disturbance in attention
  • Cerebration impaired
  • Ocular hyperaemia
  • Vision blurred
  • Influenza like illness
  • Psychomotor retardation
  • Balance disorder
  • Neck pain
  • Appetite disorder
  • Asthenopia
  • Chest pain
  • Chest discomfort
  • Contusion
  • Diarrhoea
  • Gastrooesophageal reflux disease
  • Labyrinthitis
  • Menorrhagia
  • Neck injury
  • Skin wrinkling
  • Burning sensation
  • Lower respiratory tract infection
  • Abdominal discomfort
  • Abdominal tenderness
  • Abnormal dreams
  • Dizziness postural
  • Muscle contractions involuntary
  • Dry throat
  • Frequent bowel movements
  • Depressed mood
  • Disinhibition
  • Blood pressure increased
  • Vulvovaginal dryness
  • Stress
  • Binge eating
  • Throat irritation
  • Sleep disorder
  • Exposure to toxic agent
  • Altered visual depth perception
  • Nausea
  • Decreased appetite
  • Anxiety
  • Arthritis
  • Bronchitis
  • Cerebrovascular disorder
  • Infection
  • Constipation
  • Cough
  • Cystitis
  • Bladder pain
  • Cystitis noninfective
  • Dysphagia
  • Dysarthria
  • Osteoarthritis
  • Arthropathy
  • Dysgeusia
  • Dyspnoea
  • Oedema
  • Body temperature increased
  • Flatulence
  • Gastroenteritis
  • Hallucination
  • Hyperglycaemia
  • Hypertension
  • Hypertension worsened
  • Hypoaesthesia
  • Orthostatic hypotension
  • Illusion
  • Perceptual disturbance
  • Menstrual disorder
  • Nervousness
  • Tension
  • Pallor
  • Paraesthesia
  • Pruritus
  • Rhinitis
  • Scleritis
  • Speech disorder
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Thirst
  • Tinnitus
  • Tremor
  • Urinary incontinence
  • Vaginal inflammation
  • Vaginal infection
  • Vomiting
  • Injury
  • Stupor
  • Depressed level of consciousness
  • Alertness decreased
  • Agitation
  • Mood swings
  • Affect lability
  • Migraine
  • Eye pain
  • Alanine aminotransferase increased
  • Discomfort
  • Ill-defined disorder
  • Eye irritation
  • Hyperhidrosis
  • Amnesia
  • Irritability
  • Abscess
  • Aggression
  • Aggressive reaction
  • Anaphylactic shock
  • Anaphylactoid reaction
  • Anaemia
  • Anaemia macrocytic
  • Anger
  • Rage
  • Angina pectoris
  • Angioedema
  • Arrhythmia
  • Arteritis
  • Bronchospasm
  • Conjunctivitis
  • Ulcerative keratitis
  • Libido decreased
  • Disturbance in sexual arousal
  • Delusion
  • Dental caries
  • Depersonalisation
  • Drug tolerance
  • Dysuria
  • Enteritis
  • Epistaxis
  • Eructation
  • Oesophageal spasm
  • Flushing
  • Furuncle
  • Gastritis
  • Glaucoma
  • Gout
  • Haemorrhoids
  • Herpes simplex
  • Herpes zoster
  • Hyperbilirubinaemia
  • Hypercholesterolaemia
  • Hyperlipidaemia
  • Hypersensitivity
  • Allergy aggravated
  • Hypotension
  • Conversion disorder
  • Intestinal obstruction
  • Renal failure acute
  • Laryngitis
  • Leukopenia
  • Breast pain
  • Hypotonia
  • Muscle relaxant therapy
  • Myocardial infarction
  • Acute coronary syndrome
  • Neuralgia
  • Neuritis
  • Neuropathy peripheral
  • Neuropathy
  • Neurosis
  • Nocturia
  • Otitis externa
  • Otitis media
  • Pain
  • Paresis
  • Personality disorder
  • Phlebitis
  • Pneumonia
  • Polyuria
  • Urine output increased
  • Pulmonary oedema
  • Pulmonary embolism
  • Purpura
  • Vascular purpura
  • Pyelonephritis
  • Restless legs syndrome
  • Sciatica
  • Salivary hypersecretion
  • Somnambulism
  • Suicide attempt
  • Tendonitis
  • Tetany
  • Thrombosis
  • Pollakiuria
  • Urticaria
  • Varicose vein
  • Ventricular tachycardia
  • Weight decreased
  • Yawning
  • Urinary retention
  • Apathy
  • Flat affect
  • Photopsia
  • Hypokinesia
  • Panic attack
  • Drug withdrawal syndrome
  • Periorbital oedema
  • Blood urea increased
  • Red blood cell sedimentation rate increased
  • Injection site inflammation
  • Mania
  • Muscular weakness
  • Blood alkaline phosphatase increased
  • Aspartate aminotransferase increased
  • Accommodation disorder
  • Photosensitivity reaction
  • Increased appetite
  • Proctalgia
  • Rectal tenesmus
  • Anorectal discomfort
  • Abnormal behaviour
  • Thinking abnormal
  • Mental disability
  • Respiratory depression
  • Pulmonary function test decreased
  • Saliva altered
  • Dermatitis bullous
  • Haemoglobinaemia
  • Lacrimal disorder
  • Hepatic enzyme increased
  • Erectile dysfunction
  • Rectal haemorrhage
  • Extrasystoles
  • Chills
  • Lymphadenopathy
  • Dementia
  • Face oedema
  • Altered state of consciousness
  • Renal pain
  • Gait disturbance
  • Menopausal symptoms
  • Hot flush
  • Infestation
  • Libido disorder
  • Aphasia
  • Fibroadenoma of breast
  • Breast neoplasm
  • Parosmia
  • Mental disorder
  • Breast disorder
  • Connective tissue disorder
  • Eye disorder
  • Gastrointestinal disorder
  • Cardiac disorder
  • Mediastinal disorder
  • Erythema
  • Urethral disorder
  • Urinary tract disorder
  • Malnutrition
  • Skin disorder
  • Psychiatric symptom
  • Memory impairment
  • Stomatitis
  • Drug interaction
  • Pharmacokinetic interaction
  • Major depression

Indications

  • Insomnia
  • Primary insomnia

Subjective effects []

0xea / Zolpidem []
Routes:
  • Oral (10 - 20mg)
Forms:
  • Tartrate
Effects:
  • moderate
  • strange thoughts and dreams
  • visual thoughts
a1ko / Zolpidem []
Routes:
  • Oral (20mg)
bonzi / Zolpidem []
Routes:
  • Oral (5 - 15mg)
emily / Zolpidem []
Routes:
  • Oral (10mg)
Effects:Notes:
  • light hangover
magnus / Zolpidem []
Routes:
  • Oral
Forms:
  • Tartrate
nervewing / Zolpidem []
Pilz / Zolpidem []
Routes:
  • Oral (2.5 - 10mg)
  • Sublingual (2.5 - 5mg)
Forms:
  • Tartrate
Source:
  • Zolpidem tablets BP 10mg
Indication:Effects:Notes:
  • Very good sleep-aid when melatonin isn't enough anymore.
  • Very little hangover effects, even when taken in the middle of the night
  • Can even be pretty effective when taken in doses as low as 2.5mg

Experience reports

Reddit

There are currently 6 trip reports involving zolpidem on : []

 []

  • Australia: Zolpidem is a Schedule 4.[11]
  • Brazil: Zolpidem is a B1.[12]
  • Canada: Zolpidem is a Schedule IV.
  • Germany: Zolpidem is Prescription only/Anlage III.
  • New Zealand: Zolpidem is a Class C5 (very rarely prescribed).
  • United Kingdom: Zolpidem is a Class C under the "Misuse of Drugs Act 1971".
  • United States: Zolpidem is a Schedule IV under the "Controlled Substances Act".[13]
  • United Nations: Zolpidem is a Psychotropic Schedule IV.
  • Other: Zolpidem is a SE: Förteckning IV, In general: ℞ (Prescription only).[14]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 5732, Zolpidem. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5732
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Zolpidem. UNII: 7K383OQI23. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/7K383OQI23
  3. Neubauer D. ZolpiMistTM: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US. Nature and Science of Sleep. 10 May 2010; 2:79–84. PMID 23616700. https://doi.org/10.2147/nss.s6431
  4. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clinical Pharmacokinetics. September 1995; 29(3):142–153. PMID 8521677. https://doi.org/10.2165/00003088-199529030-00002
  5. Bouchette D, Akhondi H, Patel P, Quick J. Zolpidem. StatPearls. 29 February 2024. https://www.ncbi.nlm.nih.gov/books/NBK442008/
  6. Monti JM, Spence DW, Buttoo K, Pandi-Perumal SR. Zolpidem's use for insomnia. Asian Journal of Psychiatry. February 2017; 25:79–90. PMID 28262178. https://doi.org/10.1016/j.ajp.2016.10.006
  7. Kirkwood C, Neill J, Breden E. Zolpidem modified-release in insomnia. Neuropsychiatric Disease and Treatment. 2007; 3(5):521–526. PMID 19300582.
  8. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology. July 1999; 48(1):89–97. PMID 10383565. https://doi.org/10.1046/j.1365-2125.1999.00953.x
  9. Yaripour S, Mohammadi A, Esfanjani I, Walker R, Nojavan S. Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis. EXCLI Journal. 23 April 2018; 17:349–361. PMID 29805344. https://doi.org/10.17179/excli2018-1140
  10. Ries RK. Principles of addiction medicine. Wolters Kluwer/Lippincott Williams & Wilkins. 2009. https://books.google.com/books?id=j6GGBud8DXcC&pg=PA106
  11. Scheduling of zolpidem (Stilnox). Therapeutic Goods Administration (TGA). 21 February 2008. https://www.tga.gov.au/scheduling-zolpidem-stilnox
  12. RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  13. Ambien- zolpidem tartrate tablet, film coated. DailyMed. 29 August 2019. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452
  14. Stilnoct, Filmdragerad tablett 10 mg. FASS. 2 January 2025. https://fass.se/health/product/19940128000064/fass-text

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 07:14:53
drugsprook2026-11-20 07:14:49
erowidmissing (no Erowid substance of that name)2026-11-20 07:14:49
gsrsok2026-11-20 07:14:52
hmdbmissing (hmdb.ca refused automated access to HMDB0005023)2026-11-20 07:14:49
keggok2026-11-20 07:14:52
pubchemok2026-11-20 07:14:49
redditok2026-11-20 07:14:49
siderok2026-11-20 07:14:49
structureok2026-11-20 07:14:49
wikipediaok2026-11-20 07:14:50